

(51) International Patent Classification⁶:

G01N 33/574, C07K 16/36

A1

(11) International Publication Number:

WO 98/55872

(43) International Publication Date: 10 December 1998 (10.12.98)

(21) International Application Number: PCT/US98/11162

(22) International Filing Date: 2 June 1998 (02.06.98)

(30) Priority Data:

60/048,405	3 June 1997 (03.06.97)	US
60/060,088	26 September 1997 (26.09.97)	US

(71) Applicant (for all designated States except US): AMDL, INC.
[US/US]; Suite 106, 14272 Franklin Avenue, Tustin, CA 92780-7017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CRESS, Michael, C. [US/US]; 1025 Cabrillo Park Drive, Santa Ana, CA 92701 (US). MOORE, Ronald, J. [US/US]; 1302 Ocean Drive, Hermosa Beach, CA 90254 (US). NGO, That, T. [US/US]; 20 Sandstone, Irvine, CA 92604 (US).

(74) Agent: WOOD, William, J.; Merchant, Gould, Smith, Edell, Welter & Schmidt, Suite 400, 11150 Santa Monica Boulevard, Los Angeles, CA 90025-3395 (US).


(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: IMMUNOASSAY FOR THE DETECTION OF CANCER

CLINICAL PERFORMANCE OF FDP
NORMAL vs FIVE TYPES OF CANCER (n=50)

(57) Abstract

The present invention relates to a broad cancer immunoassay. Specifically, an immunoassay for peptides associated with oncogenic processes such as metastatic proteolysis is disclosed. In an illustrative embodiment, the immunoassay utilizes antibodies which bind to peptides which are generated by proteolytic processes and which contain epitopes which are masked in undegraded blood proteins such as fibrinogen. Detection of such degradation peptides in a biological sample by immunological methods allows the diagnosis of a wide variety of cancers.